Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL) (Case T-215/20)
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Not the law itself: Notice
Address https://gelex.eu/eli/EU/notice/oj/C/2021/310/30@2021-06-16/en
Contents
EU trade markInvalidity proceedingsEU word mark HYALArticle 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001)Absolute ground for refusalArticle 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001)Right to be heardAudi alteram partem ruleObligation to state reasonsSound administration and equal treatmentArticle 165(1) of Regulation 2017/10012021/C 310/30Language of the case: English Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers) Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska, V. Ruzek and H. O’Neill, acting as Agents) Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Ioulia and Irene Tseti Pharmaceutical Laboratories SA (Athens, Greece) (represented by: C. Chrysanthis, P.-V. Chardalia and A. Vasilogamvrou, lawyers) Action brought against the decision of the Fifth Board of Appeal of EUIPO of 24 January 2020 (Case R 613/2019-5), relating to invalidity proceedings between Ioulia and Irene Tseti Pharmaceutical Laboratories and Fidia farmaceutici. The Court:
1. Dismisses the action;
2. Orders Fidia farmaceutici SpA to pay the costs.